Cite
HARVARD Citation
Van Herpen, C. et al. (n.d.). 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. European journal of cancer. pp. S65-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Van Herpen, C. et al. (n.d.). 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. European journal of cancer. pp. S65-. [Online].